Clinical study on personalized treatment for advanced NSCLC guided by ERCC 1 protein detection
Zhi-Qiang Gao,Ai-Qin Gu,Jie Shen,Hui-Min Wang,Li-Yan Jiang,Hua Zhong,Chun-Lei Shi,Jin-Su Huang,Yi-Zhuo Zhao,Li-Wen Xiong,Bo Jin,Tian-Qing Chu,Bao-Hui Han
2017-01-01
Abstract:Background & Objective: Excision repair cross complementing 1 (ERCC1) participates in the resistance of non-small cell lung cancer (NSCLC) to platinum-based chemotherapy drug. This study aimed to explore the role of ERCC1 protein expression in personalized treatment for advanced NSCLC patient and its significance. Method: From January 2010 to December 2011, 159 advanced stage (stage IIIB-IV) NSCLC patients were enrolled. The expression of ERCC1 protein in lung cancer tissue of the patient was detected by immunohistochemical method. In a ratio of 2:1, patients were randomly divided into either the personalized treatment group or the standard treatment group. The standard treatment group adopted the platinum-based chemotherapy regimen, namely, gemcitabine/cisplatin or navelbine/cisplatin. In personalized treatment group, patients with high ERCC1 protein expression received gemcitabine/navelbine, and those with low ERCC1 protein expression received gemcitabine/cisplatin or navelbine/ cisplatin. The main observed indices included response rate, overall survival and time to progression. Group comparison was conducted by chi-square test. Comparison of one-year survival rate and survival was conducted by Life table and Kaplan-Meier method. Results: Follow-up data were up to December 31, 2014. The response rate of the standard treatment group and the personalized treatment group was 26.4% and 27.4%, respectively. The difference of the two groups was not statistically significant (P=0.899). The median survival was 9.4 months (95% CI was 7.88-10.92 months) in the standard treatment group and 13.2 months (95% CI was 12.34-14.06 months) in the personalized treatment group. The difference of two groups was statistically significant (P=0.045). The time to progression was 5.0 months (95% CI was 3.84-6.16 months) in the standard treatment group and 4.7 months (95% CI was 4.03-5.37 months) in the personalized treatment group, without significant difference (P=0.369). The one-year survival rate of the standard treatment group and the personalized treatment group was 41.5% and 46.2%, respectively, without significant difference (chi-square value=0.318, P=0.572). Conclusion: Compared with the standard treatment group, the median survival of the personalized treatment group is extended. However, the personalized treatment for advanced NSCLC guided by ERCC1 protein detection does not show advantages in response rate, survival and time to progression. Additional clinical studies are needed to optimize the detection of biomarkers so as to guide reasonable selection of clinical chemotherapy regimens.